Stereotactic body radiotherapy extends the clinical benefit of pd-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

HIGHLIGHTS

• who: Jing Lin from the Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, Fujian Province, China have published the research: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma, in the Journal: (JOURNAL) of August/27,/2020
• what: To further evaluate the efficacy of PD-1 inhibitors and its combination with SBRT in recurrent/metastatic NPC patients, the authors report the experience in eight RM-NPC patients who were treated in Macao Clinics and the institution .
• how: The results . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.